Clinical Trial Update: Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports Phase 2/3 results for Sebelipase alfa in children with growth failure due to lysosomal acid lipase deficiency (incl. Wolman d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lysosomal Acid Lipase Deficiency
• Wolman Disease

Drugs mentioned

• Sebelipase alfa (sebelipase alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Lysosomal Acid Lipase Deficiency, Wolman Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-04-18